GILD — Gilead Sciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Gilead Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	27,305	27,281	27,116	28,754	29,443
Cost of Revenue
Gross Profit	20,704	21,624	21,097	22,503	23,213
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	17,387	19,951	19,511	27,092	19,421
Operating Profit	9,918	7,330	7,605	1,662	10,022
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,278	5,814	6,859	690	9,796
Provision for Income Taxes
Net Income After Taxes	6,201	4,566	5,612	479	8,510
Minority Interest
Net Income Before Extraordinary Items
Net Income	6,225	4,592	5,664	479	8,510
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,225	4,592	5,665	480	8,510
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	5.07	6.78	6.15	7.61	8.16
Dividends per Share